Tag: squamous cell carcinoma

Home / squamous cell carcinoma

Categories

Retifanlimab-dlwr with carboplatin and paclitaxel is approved by the USFDA and as a single agent for squamous cell carcinoma of the anal canal

On May 15, 2025, the Food and Drug Administration sanctioned retifanlimab-dlwr (Zynyz, Incyte Corporation) in conjunction with carboplatin and paclitaxel for the initial treatment of people with inope...
squamous-cell-carcinoma

We Are Online! Chat With Us!
Scan the code